News
Public · Published
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
A US judge rejected Novo Nordisk's request to block Eli Lilly from continuing advertisements for weight-loss drugs that Novo Nordisk considered false and misleading. The judge said Novo Nordisk did not deserve a preliminary injunction because it failed to show the ads threatened sales or caused lasting damage.
Published:
Updated:
What happened
A US judge rejected Novo Nordisk's request to block Eli Lilly from continuing advertisements for weight-loss drugs that Novo Nordisk considered false and misleading. The judge said Novo Nordisk did not deserve a preliminary injunction because it failed to show the ads threatened sales or caused lasting damage.
Confirmed
Global impact / market context
The ruling lets Eli Lilly keep running ads comparing Zepbound and Mounjaro with Wegovy and Ozempic in markets worth tens of billions of dollars in yearly sales. Novo Nordisk must now argue its false advertising case without an immediate stop to the commercials, so the dispute continues.
Analyst inference
The two companies compete in obesity and diabetes treatments where advertising can sway which drug doctors and patients choose. Because the judge found no proven sales or reputation harm yet, investors get no near-term signal that Lilly must change its marketing or that Novo gains relief.
Analyst inference
What to watch
- Novo Nordisk said the ruling did not decide whether Lilly's advertising is false and misleading, and that the litigation is still ongoing. Confirmed
- Watch whether Novo Nordisk seeks a full trial or other court action to challenge the ads, since its request for a preliminary injunction, which means an early court order to stop conduct, was rejected. Proposed
- Track whether doctors and patients shift prescriptions toward Zepbound or Mounjaro as the ads stay on air, because that could affect each company's revenue and investor positioning in obesity drugs. Analyst inference
Evidence
- Original source link unavailable